e-learning
resources
Munich 2006
Sunday 03.09.2006
Recent update on asthma treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations
versus
a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
P. Kuna, M. J. Peters, R. Buhl (Lodz, Poland; Concord, Australia; Mainz, Germany)
Source:
Annual Congress 2006 - Recent update on asthma treatment
Session:
Recent update on asthma treatment
Session type:
Thematic Poster Session
Number:
1228
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Kuna, M. J. Peters, R. Buhl (Lodz, Poland; Concord, Australia; Mainz, Germany). Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations
versus
a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Eur Respir J 2006; 28: Suppl. 50, 1228
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy
Source: Eur Respir J 2010; 36: 524-530
Year: 2010
Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Source: Eur Respir J 2005; 26: 819-828
Year: 2005
Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Budesonide/formoterol maintenance and reliever therapy at two different maintenance doses
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017
Year: 2018
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001
Do symptomatic asthmatic smokers need a higher maintenance dose when treated with budesonide/formoterol maintenance and reliever therapy than non-smokers?
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Budesonide/formoterol maintenance and reliever therapy – effective treatment at a lower cost
Source: Annual Congress 2008 - Rationale of self-education in asthma therapy
Year: 2008
Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005
Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001
Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Once-daily budesonide/formoterol
via
a single inhaler is effective in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001
Formoterol turbuhaler is effective and safe compared with salbutamol by pMDI and spacer as reliever therapy in patients with acute severe asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 52s
Year: 2002
Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 616s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept